This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Reference
Wu B, et al. Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy. Journal of Thoracic Oncology : 31 Oct 2017. Available from: URL: http://doi.org/10.1016/j.jtho.2017.10.012
Rights and permissions
About this article
Cite this article
Osimertinib not cost effective for advanced NSCLC with mutation. PharmacoEcon Outcomes News 791, 22 (2017). https://doi.org/10.1007/s40274-017-4506-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4506-6